
At ADA 2024, Breakthrough T1D-funded research takes center stage
Here is Aaron J. Kowalski, Ph.D., C with the key takeaways from the conference and below is a written summary…

C-Peptide as an Endpoint in Clinical Trials: Its Time Has Come
A new publication provides more evidence for C-peptide as a validated surrogate to predict clinical benefits of disease-modifying therapies in…

Beating the Odds: The Improbable Story of How Perseverance, Belief, and Luck Led to the Approval of the First Life-Changing Immune Therapy for Type 1 Diabetes
The true story of how Tzield (teplizumab), the first disease-modifying therapy approved for use in delaying type 1 diabetes (T1D)…

ATTD Brings Together Top Minds in Diabetes Research
Leading researchers gathered for the ATTD meeting, which featured more than 50 studies presented by Breakthrough T1D-funded researchers.

Top Researchers Gather for the 17th ATTD Conference
This year’s Advanced Technologies & Treatments for Diabetes (ATTD) meeting, which will be held on March 6-9, will have 50…

Breakthrough T1D T1D Fund Invests in vTv Therapeutics
With an investment from the Breakthrough T1D T1D Fund, vTv Therapeutics will run a phase III clinical trial of cadisegliatin…

World-Renowned Researchers Gather at the Breakthrough T1D-nPOD Annual Meeting
Leading researchers gathered in Long Beach, California, for the 16th annual meeting of the Network for Pancreatic Organ Donors with…

Bench to Bedside: Breakthrough T1D-nPOD Conference
Leading scientists will gather for the annual meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD), held February…

We are Grateful to be a Part of the T1D Community
In 2023, we have made tremendous progress in accelerating cures, improving lives, and advocating for people with T1D and their…

FDA-Approved Immune Therapy Shows Benefit in Newly Diagnosed
In a Breakthrough T1D-funded clinical trial and published in the New England Journal of Medicine, baricitinib preserved beta cell function…